Research Article

IFN-γ-Secreting-Mesenchymal Stem Cells Exert an Antitumor Effect In Vivo via the TRAIL Pathway

Xinyuan Yang,1 Jingchun Du,2 Xia Xu,2 Chun Xu,2 and Wu Song3

1 Department of Gynecology and Obstetrics, First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an 710061, China
2 Kingmed College of Laboratory Medicine, Guangzhou Medical University, Guangzhou 510182, China
3 Department of Gastrointestinal-Pancreatic Surgery, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 51800, China

Correspondence should be addressed to Jingchun Du; hnxydjc@126.com and Wu Song; songwu@mail.sysu.edu.cn

Received 10 March 2014; Revised 5 May 2014; Accepted 5 May 2014; Published 26 May 2014

Academic Editor: Yi Zhang

Copyright © 2014 Xinyuan Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mesenchymal stem cells (MSCs) can exhibit either prooncogenic or antitumor properties depending on the context. Based on our previous study, we hypothesized that MSCs engineered to deliver IFN-γ would kill cancer cells through persistent activation of the TRAIL pathway. Human bone-marrow (BM-) derived MSCs were isolated, amplified, and transduced with a lentiviral vector encoding the IFN-γ gene under the control of the EF1α promoter. The IFN-γ-modified MSCs effectively secreted functional IFN-γ, which led to long-term expression of TRAIL. More importantly, the IFN-γ-modified MSCs selectively induced apoptosis in lung tumor cells through caspase-3 activation within the target cells. The percentage of activated-caspase-3-positive tumor cells in IFN-γ-modified MSCs cocultures was significantly higher than in control MSCs cocultures. Treatment with anti-TRAIL antibody dramatically suppressed the caspase-3 activation observed in H460 cells. After injection into nude mice, the IFN-γ-modified MSCs inhibited the growth and progression of lung carcinoma compared with control cells. Collectively, our results provide a new strategy for tumor therapy that utilizes IFN-γ-modified MSCs.

1. Introduction

Mesenchymal stem cells (MSCs) are derived from the mesodermal germ layer and can be easily isolated and cultured from many tissues, such as bone marrow, adipose tissue, and amniotic fluid [1–3]. Because MSCs exhibit low expression of MHC I and do not express MHC II molecules, these cells do not cause immunological reaction and rejection after they are infused into an allogenic body [4, 5]. In addition, other reports have indicated that MSCs exhibit tropism toward tumors [6]. Therefore, MSCs are considered a promising cellular carrier for tumor gene therapy. For example, IFN-α-engineered MSCs can halt tumor growth in vivo by activating immune cells [7], and MSCs modified with pigment epithelium-derived factor can inhibit hepatocellular carcinoma growth in vivo by decreasing angiogenesis [8].

In addition to isolation from normal tissue, MSCs have also been found in tumor tissue and may be a key source of tumor-associated stromal cells [9, 10]. The current evidence suggests that the role of MSCs in tumor survival and progression is complex and diverse [11]. In our previous report, IFN-γ-primed MSCs were shown to express tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which causes apoptosis in tumor cells [12]. However, the expression of TRAIL only persisted for approximately seventy-two hours after one priming with IFN-γ. We therefore evaluated whether IFN-γ-secreting mesenchymal stem cells could exert a persistent antitumor effect via the TRAIL pathway.

In this study, we show that IFN-γ-modified MSCs continuously express TRAIL and induce apoptosis in lung cancer cells by activating caspase-3 within the target cells. In vivo models further confirm the antitumor effect of the IFN-γ-secreting MSCs.

2. Materials and Methods

2.1. Isolation, Expansion, and Differentiation of MSCs. According to a policy approved by our institutional ethics
committee, heparinized human bone marrow (BM) samples were obtained by iliac crest aspiration from healthy donors who had given informed consent. MSCs were isolated and cultured as previously described [12]. Briefly, BM aspirates were diluted with an equal volume of low-glucose, complete DMEM and then fractionated with Lymphoprep solution (Huajin, Shanghai, China). The mononuclear cells were collected, washed, plated in 75 cm² flasks, and incubated at 37°C under 5% CO₂. After 3 days of culture, the nonadherent cells were removed by replacing the medium, and the adherent cells were continuously cultured with a change of the medium every 3 days. The MSCs were digested and replated when they reached approximately 90% confluence.

Osteogenic differentiation of the MSCs was induced using low-glucose, complete DMEM supplemented with 0.1 μM dexamethasone (Sigma-Aldrich, St. Louis, MO), 50 μg/L vitamin C (Sigma-Aldrich), and 10 mM β-glycerophosphate (Calbiochem, San Diego, CA). The medium was replaced every 2-3 days. Around day 15, the mineralization of the MSCs was assessed by staining with 0.5% alizarin red solution with a loosened cap. The medium was replaced every 3 days. The isolated cell lines were defined as MSCs IFN-γ, MSCshrGFP, 3T3 hrGFP, 293F ThrGFP, H460 hrGFP, H1299 hrGFP, A549 hrGFP, and MCF-7 hrGFP, respectively.

2.4. Real-Time PCR. Total RNAs were extracted from undifferentiated and differentiated MSCs using TRIzol reagent according to the manufacturer's instructions (Invitrogen). After digestion with DNase I (Fermentas, Burlington, Canada), 1 μg total RNA was reverse-transcribed using RevertAid first strand complementary DNA synthesis kit (Fermentas). All quantitative real-time PCR assays were performed on CFX Connect Detection System (Bio-Rad, Hercules, CA, USA) using SYBR Green I Master Mix (TOYOBO, Osaka, Japan). All reactions were run in triplicate. Relative quantification (RQ) was performed by normalizing the expression of target gene to that of GAPDH, used as a reference. The minimally normalized detectable target gene expression level was assigned a value of unity, and the other values reflect fold changes compared with this minimal level. The primer sequences used in this study were as follows: osteocalcin: 5'-CAC TCC TCG CCC TAT TGG C-3' and 5'-CCC TCG TGC TTG GAC ACA AAG-3'; α2P2, 5'-AGG ACC ATA ACC TTA GAT G-3' and 5'-CGT GGA AGT GAC GCC TTG C-3'; collagen I: 5'-CAG CCG CTT CAT CTA CAG C-3' and 5'-ATT ATT CAA TCA CTT GCT T-3'; and GAPDH: 5'-GAA GGT GAA GGT CCG ATG C-3' and 5'-GAA GAT GGT GAG ATT TTC-3'.

2.5. ELISA. The supernatant media derived from the control MSCs, MSCs IFN-γ, and MSCs hrGFP were collected, and the IFN-γ in these media was measured using a human IFN-γ ELISA kit (ebioScience, San Diego, CA) according to the manufacturer's instructions.

2.6. Western Blots (WB). MSCs were first primed with IFN-γ (20 ng/mL). After 12 hours, the medium was replaced with normal low-glucose complete DMEM, and the cultures were maintained for 72 hours. Thereafter, the MSCs were

---

2.2. Construction of Lentiviral Vectors. The sequence encoding human IFN-γ (Funeng, Guangzhou, China) was first amplified using primer 1 (5'-GGGG ACA AGT TTG TAC AAA GCA GGCT GCC ACC ATG AAA TAT ACA AGT TAT ATC TTG GCT TTTT3') and primer 2 (5'-GGGG ACC ACT TTG TAC AAG AAA GCT GGG T TTA CTG GGA TGC TCT TCG ACC TC-3'). After gel-purification, the PCR products were cloned into pDONR 221 through a BP recombination reaction following the manufacturer's instructions (Invitrogen, Carlsbad, CA) to generate the entry clone pDown-IFN-γ. Then, pUp-EFlx and pDown-IFN-γ were recombined into pDESTpuro through an LR recombination reaction to construct the expression vector pLV/Final-puro-EFlx-IFN-γ. Finally, PCR and sequencing were used to identify clones with the correct recombination events.

2.3. Lentivirus Construction and Transfection. The lentiviral particles carrying the IFN-γ or humanized Renilla GFP genes were prepared by transient cotransfection of pLV/Final-puro-EFlx-IFN-γ or pLV/Final-puro-EFlx-hrGFP with a lentiviral packaging mix (Invitrogen) into 293FT cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. After 48 hours, the viral particles were harvested, filtered through a 0.45 μm polyethersulfone membrane, and concentrated by ultracentrifugation. Human MSCs were transduced with the lentiviral particles carrying IFN-γ or hrGFP at a multiplicity of infection of 50. At the same time, the 3T3, 293FT, H460, H1299, A549, and MCF-7 cell lines were transduced with lentiviral particles carrying only hrGFP using the same protocol. After two rounds of infection, 1–5 μg/mL puromycin was added to the culture medium, and these cultures were maintained for 2-3 days. The isolated cell lines were defined as MSCs IFN-γ, MSCs hrGFP, 3T3 hrGFP, 293FT hrGFP, H460 hrGFP, H1299 hrGFP, A549 hrGFP, and MCF-7 hrGFP, respectively.

---

2.6. Western Blots (WB). MSCs were first primed with IFN-γ (20 ng/mL). After 12 hours, the medium was replaced with normal low-glucose complete DMEM, and the cultures were maintained for 72 hours. Thereafter, the MSCs were
repeatedly primed with IFN-γ for 12 hours and then again maintained in normal medium for 24 hours. At different time points, the MSCs were washed with cold PBS and lysed in Laemmli buffer. The cell lysates were denatured at 100°C for 5 min and centrifuged at 12,000 g for 10 min at 4°C. The supernatants were recovered, separated by 12% SDS-PAGE, and transferred onto 0.45 μm PVDF membranes (Millipore, Bedford, MA). After blocking with TBS-Tween-20 (0.1%) containing 5% nonfat milk for 1 hour at room temperature, the PVDF membranes were incubated with the appropriate primary antibodies (anti-TRAIL or anti-GAPDH antibody) overnight at 4°C. Specifically bound primary antibodies were detected by peroxidase-coupled secondary antibodies and chemiluminescence (Cell Signaling Technologies, Beverly, MA). In addition, the expression of TRAIL in MSCs only lasted approximately 72 hours after one IFN-γ-priming. However, these MSCs continued to express TRAIL if they were primed again with IFN-γ (Figure 1(c)).

3.2. MSCs Could Be Genetically Modified with IFN-γ to Express TRAIL. The lentiviral expression vector pLV/Final-puro-EFlα-IFN-γ was constructed using multisite gateway technology and then confirmed by PCR (Figure 2(a)) and DNA sequencing (data not shown). Lentivirus particles containing the IFN-γ or hRFP genes were constructed in 293FT cells. MSCs were then transduced with the lentiviral particles. After puromycin selection, more than 90% of the MSCs were hRFP-modified (Figure 2(b)). Because the transductions were performed in parallel, it could be inferred that transduction efficiencies were similar to both the IFN-γ virus and the hRFP virus. Moreover, ELISA results indicated that MSCs IFN-γ efficiently secreted IFN-γ (Figure 2(c)). Western blot results indicated that MSCs IFN-γ synthesized TRAIL at P2 and P5 passages, respectively (Figure 2(d)). On the other hand, the immunophenotype, differentiation potential, and proliferation property of MSCs IFN-γ were not dramatically changed, compared with those of MSCs (see Figure S1 in the Supplementary Material available online at http://dx.doi.org/10.1155/2014/318098).

3.3. IFN-γ-Secreting MSCs Selectively Induce Apoptosis in Tumor Cells In Vitro. As shown in Figures 3(a)–3(f), MSCs IFN-γ induced apoptosis in H460, H1299, A549, and MCF-7 cancer cells, but not in 3T3 and 293FT cells; apoptosis was evident by the detachment of GFP-positive target cells and the appearance of cellular debris and apoptotic bodies in GFP-positive cells. The observed cell viability, as detected by the CCK-8 kit, also indicated that MSCs IFN-γ inhibited the proliferation of the transformed tumor cells to a greater extent than control MSCs (P < 0.05) (Figure 3(g)).

3.4. IFN-γ-Secreting MSCs Kill Tumor Cells by TRAIL-Mediated Caspase-3 Activation. To further explore the mechanisms underlying MSCs IFN-γ-induced apoptosis, the activation of caspase-3 within target cells was measured. As shown in Figure 4, the percentage of H460 cells positive for activated caspase-3 was significantly higher for those cocultured with MSCs IFN-γ than those cocultured with control MSCs (27.1 ± 5.6% at 24 h and 41.7 ± 5.0% at 48 h compared with 1.6 ± 0.8% at 24 h and 1.6 ± 0.5% at 48 h, resp., P < 0.01). However, treatment with an anti-TRAIL antibody dramatically suppressed the observed caspase-3 activation in H460 cells (11.8±6% at 24 h and 27.9±5.7% at 48 h, P < 0.05). These results indicate that MSCs IFN-γ effectively induce apoptosis in tumor cells by activating caspase-3 within the target cells and reveal the TRAIL-mediated cytotoxic effect of MSCs IFN-γ.
3.5. IFN-γ-Secreting MSCs Exhibit Antitumor Activity In Vivo.

To evaluate the cytotoxicity of MSCs IFN-γ in vivo, xenograft tumor model of lung carcinoma was established, and the kinetics of tumor mass growth in nude mice were recorded. As shown in Figure 5(a), at approximately 20 days, tumor masses were observed in mice injected with H460 cells alone. The inclusion of MSCs IFN-γ delayed the appearance of tumors and inhibited the growth of the tumor mass. Finally, the tumor masses among the three groups had significantly different weights (0.45±0.09 g in the H460 group, 0.21±0.04 g in the MSCs IFN-γ group, and 0.72±0.26 g in the MSCs group, P < 0.05). Correspondingly, hematoxylin and eosin staining indicated that tumor derived from the mixture of H460 and MSCs IFN-γ displayed dramatically tissue necrosis such as hemorrhagic region and fractured nuclei, compared with the other two groups (Figures 5(b)-5(c)).

4. Discussion

As mesoderm-derived progenitor cells, MSCs can home to tumor tissues through the chemotactic action of inflammatory factors [15]. However, the effects of MSCs on the growth and progression of tumors are still debated. For example, Kidd et al. reported that BM- and adipose-derived MSCs may be recruited by ovarian and breast tumors, are induced to become tumor-associated fibroblasts and vascular stromal cells, and promote tumor progression [16]. Luo et al. reported that BM-derived MSCs could promote prostate cancer metastasis via alteration of the CCL5-AR signaling pathway [15]. On the other hand, Zhu et al. reported that MSCs could inhibit K562 cell growth by secreting DKK1 [17], and Sun et al. reported that umbilical cord blood and adipose-derived MSCs could reduce lung metastasis and the growth of breast cancer cells by inducing apoptosis [18]. These results suggest that the effect of MSCs on tumors is variable and determined by the distinct tumor microenvironment and tumor type.

Alternatively, MSCs could produce variable responses under different induction conditions. For example, TLR4-primed MSCs have an antitumor effect, whereas TLR3-primed MSCs promote tumor growth and metastasis [19, 20]. Our previous report showed that IFN-γ induces MSCs to express TRAIL, which selectively mediates the apoptosis of tumor cells in vitro. However, the in vivo
effect of IFN-γ-primed MSCs on tumor growth is different than that observed in vitro [12]. A primary reason for this discrepancy may be that the MSCs stimulated only once with IFN-γ could not maintain TRAIL expression, weakening the cytotoxic effect of the IFN-γ-primed MSCs. Here, the assumption that TRAIL expression is reduced in IFN-γ-primed MSCs after the removal of IFN-γ was confirmed. However, these MSCs continued to express TRAIL if IFN-γ was again supplemented.

As a type II interferon, IFN-γ is mainly produced by lymphocytes and NK cells and plays an important role in the adaptive cellular immune response against tumors. In addition, because the IFN-γ receptor is ubiquitously expressed, IFN-γ can also influence a vast number of nonlymphoid cellular responses by upregulating the expression of a number of apoptosis-associated proteins [21, 22]. IFN-γ has been considered a promising antitumor drug. However, the clinical application of IFN-γ in protein form is hindered by serious side effects, which result from the high dose required to overcome the short half-life of the protein and to achieve significant therapeutic effects [23, 24].

Based on the work presented here, the benefits of IFN-γ may be exploited through the genetic engineering of MSCs, which are used as a cellular vector. In addition to their function as a cellular vector, MSCs also exhibit a cytotoxic response after priming with IFN-γ. To achieve the ideal transduction efficiency, a lentiviral vector system was chosen for our experiments. Compared to other genetic engineering systems, such as adenoviral or retroviral vectors, the HIV-based lentiviral vector system can stably transfect cells at different mitotic stages, which is critical for MSCs that are often quiescent [25, 26]. Several studies have reported that lentiviral vectors can effectively deliver target genes into MSCs [8, 27]. Correspondingly, our results also indicated that the IFN-γ gene could be stably inserted into MSCs, expressed, and secreted by the host cells using a lentiviral vector. At the same time, IFN-γ could induce MSCs to stably synthesize TRAIL in an autocrine or paracrine fashion.

Most importantly, our data indicate that IFN-γ-secreting MSCs exert a selective cytotoxic effect on different types of tumor cell lines, including lung cancer cells and breast cancer cells. This cytotoxicity of IFN-γ-modified MSCs is mediated by TRAIL via activation of the extrinsic apoptosis pathway. After injection into nude mice along with H460 tumor cells, IFN-γ-modified MSCs still maintained an antiproliferative effect. The antitumor effect of IFN-γ-modified MSCs is obviously enhanced compared with that of IFN-γ-primed MSCs, as previously reported [12]. However, similar to our report, this study showed that tumor growth in mice injected with H460 cells was more prominent when MSCs were included [12]. A possible reason for this phenomenon may be that the proapoptotic capacity of IFN-γ-modified MSCs is dominant over the tumor-supportive capacity of unmodified MSCs, resulting in the inhibition of tumors by IFN-γ-modified MSCs.

In conclusion, our data indicate that MSCs can be effectively modified with the IFN-γ gene using a lentiviral transduction system. The IFN-γ-modified MSCs inhibit tumor cell growth in vitro and in vivo through a TRAIL-mediated pathway. Thus, IFN-γ-modified MSCs may provide a new option for cancer therapy.
MSCs IFN-γ selectively induced apoptosis in cancer cells, but not in normal cells. MSCs IFN-γ were cocultured with 3T3 hrGFP (a), 293FT hrGFP (b), H460 hrGFP (c), H1299 hrGFP (d), A549 hrGFP (e), and MCF-7 hrGFP (f) cells for 48 hours. The mixed cells were observed using phase-contrast, GFP-specific, and DAPI-specific microscopy. The typical apoptotic and dead cells are marked. Scale bar: 200 μm. (g) The cell viability within the coculture system was measured using a CCK-8 kit and was shown as a percentage normalized to the viability of the control MSCs coculture group, which was set to 100%. The asterisks indicate $P < 0.01$. The reported results are representative of the results from three separate experiments.
MSCs IFN-γ induced tumor cell apoptosis by activating caspase-3 within the target cells, a process which was mediated by TRAIL. MSCs IFN-γ were cocultured with H460 hrGFP cells for 24 h (a) and 48 h (b) in the presence or absence of an anti-TRAIL antibody. The activated caspase-3 was detected in the H460 hrGFP cells by immunofluorescence staining. (c) The percentage of activated caspase-3-positive H460 hrGFP cells was quantified using ImagePro 5.0 (*P < 0.05, **P < 0.01). The reported results are representative of the results from three separate experiments.
Figure 5: MSCs IFN-γ inhibit tumor mass growth in nude mice. (a) Tumor sizes were dynamically monitored after H460 cells combined with or without MSCs or MSCs IFN-γ were injected into nude mice (n = 3 mice/group, three separate experiments). (b) The tumor mass weight and morphology were compared at the end of the incubation period in vivo. The asterisks indicate P < 0.05. (c) Hematoxylin and eosin (H&E) staining of xenograft tumor. Tumor mass containing MSCs IFN-γ showed a serious extent of necrotic area, compared with the other two groups.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Xinyuan Yang and Jingchun Du contributed equally to this work.

Acknowledgments

This research was supported by the National Natural Science Foundation of China (81101730) and the PhD Start-Up Fund of Guangzhou Medical University (2012C80).

References

[1] M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage potential of adult human mesenchymal stem cells,” Science, vol. 284, no. 5411, pp. 143–147, 1999.

[2] R. H. Lee, B. Kim, I. Choi et al., “Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue,” Cellular Physiology and Biochemistry, vol. 14, no. 4-6, pp. 311–324, 2004.

[3] C. Klein, J. Strobel, J. Zingsem et al., “Ex vivo expansion of hematopoietic stem- and progenitor cells from cord blood in coculture with mesenchymal stroma cells from amnion, chorion, Wharton’s jelly, amniotic fluid, cord blood, and bone marrow,” Tissue Engineering Part A, vol. 19, no. 23-24, pp. 2577–2585, 2013.
[4] K. Le Blanc and O. Ringdén, “Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation,” *Biology of Blood and Marrow Transplantation*, vol. 11, no. 5, pp. 321–334, 2005.

[5] K. Le Blanc, I. Rasmusson, B. Sundberg et al., “Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells,” *Lancet*, vol. 363, no. 9419, pp. 1439–1441, 2004.

[6] S. Kidd, E. Spaeth, J. L. Dembinski et al., “Direct evidence of mesenchymal stem cell tropism for tumor and wound healing microenvironments using in vivo bioluminescent imaging,” *Stem Cells*, vol. 27, no. 10, pp. 2614–2623, 2009.

[7] C. Xu, L. Lin, G. Cao et al., “Interferon-α-secreting mesenchymal stem cells exert potent antitumor effect in vivo,” *Oncogene*, vol. 2013, article 458, 2013.

[8] Y. Gao, A. Yao, W. Zhang et al., “Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice,” *Oncogene*, vol. 29, no. 19, pp. 2784–2794, 2010.

[9] K. McLean, Y. Gong, Y. Choi et al., “Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production,” *Journal of Clinical Investigation*, vol. 121, no. 8, pp. 3206–3219, 2011.

[10] J. T. Lin, J. Y. Wang, M. K. Chen et al., “Colon cancer mesenchymal stem cells modulate the tumorigenicity of colon cancer through interleukin 6,” *Experimental Cell Research*, vol. 319, no. 14, pp. 2216–2229, 2013.

[11] M. R. Moniri, X.-Y. Sun, J. Rayat et al., “TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells,” *Cancer Gene Therapy*, vol. 19, no. 9, pp. 652–658, 2012.

[12] J. Du, L. Zhou, X. Chen et al., “IFN-γ-primed human bone marrow mesenchymal stem cells induce tumor cell apoptosis in vitro via tumor necrosis factor-related apoptosis-inducing ligand,” *International Journal of Biochemistry and Cell Biology*, vol. 44, no. 8, pp. 1305–1314, 2012.

[13] H. Ke, P. Wang, W. Yu et al., “Derivation, characterization and gene modification of cynomolgus monkey mesenchymal stem cells,” *Differentiation*, vol. 77, no. 3, pp. 256–262, 2009.

[14] G. Grisendi, R. Bussolari, L. Cafiarelli et al., “Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy,” *Cancer Research*, vol. 70, no. 9, pp. 3718–3729, 2010.

[15] J. Luo, S. Ok Lee, L. Liang et al., “Infiltrating bone arrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling,” *Oncogene*, vol. 2013, article 233, 2013.

[16] S. Kidd, E. Spaeth, K. Watson et al., “Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma,” *PLoS ONE*, vol. 7, no. 2, Article ID e30563, 2012.

[17] Y. Zhu, Z. Sun, Q. Han et al., “Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1,” *Leukemia*, vol. 23, no. 5, pp. 925–933, 2009.

[18] B. Sun, K.-H. Roh, J.-R. Park et al., “Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model,” *Cytotherapy*, vol. 11, no. 3, pp. 289–298, 2009.

[19] R. S. Waterman, S. L. Tomchuck, S. L. Henkle, and A. M. Betancourt, “A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype,” *PLoS ONE*, vol. 5, no. 4, Article ID e10088, 2010.

[20] R. S. Waterman, S. L. Henkle, and A. M. Betancourt, “Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis,” *PLoS ONE*, vol. 7, no. 9, Article ID e45590, 2012.

[21] G. Valente, L. Ozmen, F. Novelli et al., “Distribution of interferon-γ receptor in human tissues,” *European Journal of Immunology*, vol. 22, no. 9, pp. 2403–2412, 1992.

[22] S. D. Der, A. Zhou, B. R. G. Williams, and R. H. Silverman, “Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 26, pp. 15623–15628, 1998.

[23] J. R. Jett, A. W. Maksymiuk, J. Q. Su et al., “Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer,” *Journal of Clinical Oncology*, vol. 12, no. 11, pp. 2321–2326, 1994.

[24] J. H. Schiller, M. Pugh, J. M. Kirkwood, D. Karp, M. Larson, and E. Borden, “Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design,” *Clinical Cancer Research*, vol. 2, no. 1, pp. 29–36, 1996.

[25] C. A. Kyriakou, K. L. Yong, R. Benjamin et al., “Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt’s lymphoma in a murine model,” *Journal of Gene Medicine*, vol. 8, no. 3, pp. 253–264, 2006.

[26] L. J. Chang and E. E. Gay, “The molecular genetics of lentiviral vectors—current and future perspectives,” *Current Gene Therapy*, vol. 1, no. 3, pp. 237–251, 2001.

[27] M. R. Loebinger, A. Eddaoudi, D. Davies, and S. M. Janes, “Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer,” *Cancer Research*, vol. 69, no. 10, pp. 4134–4142, 2009.